Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, January 1998, p. 114-120, Vol. 42, No. 1
Veterans Affairs Outpatient Clinic 111C,
Boston, Massachusetts 021141;
Veterans
Affairs Hospital 111B, Seattle, Washington
981082;
International Pharmaceutical
Consultants, Inc., Scarsdale, New York
105833; and
Otsuka Pharmaceuticals,
Inc., Rockville, Maryland 208504
Received 20 March 1997/Returned for modification 11 August
1997/Accepted 15 October 1997
A randomized, prospective, double-blind, double-dummy, multicenter
study investigated the efficacy and safety of 10 days of oral therapy
with grepafloxacin at 400 mg once daily, grepafloxacin at 600 mg once
daily, or ciprofloxacin at 500 mg twice daily in 624 patients with
acute bacterial exacerbations of chronic bronchitis. At the end of
treatment, clinical success (cure or improvement) was achieved for 93%
(140 of 151), 88% (137 of 156), and 91% (145 of 160) of patients in
the groups receiving grepafloxacin at 400 mg, grepafloxacin at 600 mg,
and ciprofloxacin, respectively (clinically evaluable population). At
follow-up (14 to 28 days posttreatment), the clinical success rates
were 87% (124 of 143), 81% (122 of 151), and 80% (123 of 154) in the
groups receiving grepafloxacin at 400 mg and 600 mg and ciprofloxacin,
respectively. A total of 379 pathogens were isolated from 290 patients,
with the most common isolates being Moraxella catarrhalis
(21%), Staphylococcus aureus (20%), Haemophilus
influenzae (18%), and Streptococcus pneumoniae
(7%). For the evaluable population, successful bacteriologic response
was obtained at the end of treatment for 96% (92 of 96), 98% (87 of
89), and 92% (82 of 90) of patients receiving grepafloxacin at 400 mg,
grepafloxacin at 600 mg, and ciprofloxacin, respectively, and was
maintained in 86% (82 of 95), 88% (78 of 89), and 82% (69 of 84) of
patients, respectively, at follow-up. All pretreatment S. pneumoniae isolates were susceptible to grepafloxacin, but two
strains were resistant to ciprofloxacin. All treatments were well
tolerated, with the most frequently reported drug-related adverse
events being nausea, taste perversion, and headache. All drug-related
adverse events in the grepafloxacin groups were mild or moderate in
severity. This study demonstrates that 10-day courses of grepafloxacin
given at 400 or 600 mg once daily were as effective, clinically and
bacteriologically, as ciprofloxacin given at 500 mg twice daily for the
treatment of acute bacterial exacerbations of chronic bronchitis.
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Efficacy and Safety of a 10-Day Course of 400 or
600 Milligrams of Grepafloxacin Once Daily for Treatment of Acute
Bacterial Exacerbations of Chronic Bronchitis: Comparison with a 10-Day
Course of 500 Milligrams of Ciprofloxacin Twice Daily
*
Corresponding author. Mailing address: 251 Causeway
St., VA Outpatient Clinic 111C, Boston, MA 02114. Phone: (617)
248-1277. Fax: (617) 248-1304.
Antimicrobial Agents and Chemotherapy, January 1998, p. 114-120, Vol. 42, No. 1
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Wilson, R., Allegra, L., Huchon, G., Izquierdo, J.-L., Jones, P., Schaberg, T., Sagnier, P.-P.
(2004). Short-term and Long-term Outcomes of Moxifloxacin Compared to Standard Antibiotic Treatment in Acute Exacerbations of Chronic Bronchitis. Chest
125: 953-964
[Abstract] [Full Text] -
Sethi, S., Murphy, T. F.
(2001). Bacterial Infection in Chronic Obstructive Pulmonary Disease in 2000: a State-of-the-Art Review. Clin. Microbiol. Rev.
14: 336-363
[Abstract] [Full Text] -
Georgopoulos, A., Borek, M., Ridl, W., Amoxycillin Bronchitis Study Group, T.
(2001). Randomized, double-blind, double-dummy study comparing the efficacy and safety of amoxycillin 1 g bd with amoxycillin 500 mg tds in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother
47: 67-76
[Abstract] [Full Text] -
Hirschmann, J. V.
(2000). Do Bacteria Cause Exacerbations of COPD?. Chest
118: 193-203
[Abstract] [Full Text] -
Fogarty, C. M., Bettis, R. B., Griffin, T. J., Keyserling, C. H., Nemeth, M. A., Tack, K. J.
(2000). Comparison of a 5 day regimen of cefdinir with a 10 day regimen of cefprozil for treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother
45: 851-858
[Abstract] [Full Text] -
Wilson, R., Kubin, R., Ballin, I., Deppermann, K.-M., Bassaris, H. P., Leophonte, P., Schreurs, A. J. M., Torres, A., Sommerauer, B.
(1999). Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother
44: 501-513
[Abstract] [Full Text] -
Langan, C. E., Zuck, P., Vogel, F., McIvor, A., Pierzchala, W., Smakal, M., Staley, H., Marr, C.
(1999). Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother
44: 515-523
[Abstract] [Full Text] -
(1999). New fluoroquinolone antibiotics. DTB
37: 6-8
[Abstract] [Full Text] -
Pankuch, G. A., Jacobs, M. R., Appelbaum, P. C.
(1998). Antipneumococcal Activity of Grepafloxacin Compared to That of Other Agents by Time-Kill Methodology. Antimicrob. Agents Chemother.
42: 1263-1265
[Abstract] [Full Text]
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»